Savara (SVRA) Total Non-Current Liabilities (2016 - 2025)

Savara (SVRA) reported Total Non-Current Liabilities of $50.3 million for Q4 2025, up 21.67% year-over-year from $41.3 million in Q4 2024, and up 8.09% quarter-over-quarter from $46.5 million in Q3 2025.

Savara (SVRA) Total Non-Current Liabilities (2016 - 2025) Analysis & Trends

Savara (SVRA) has 10 years of Total Non-Current Liabilities data on file, last reported at $50.3 million in Q4 2025.

  • Total Non-Current Liabilities for Q4 2025 came in at $50.3 million, up 21.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $50.3 million (up 21.67% YoY), and the FY2025 annual result was $50.3 million, up 21.67% from the prior year.
  • Total Non-Current Liabilities improved to $50.3 million in Q4 2025 per SVRA's latest filing, from $46.5 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $50.3 million in Q4 2025 and troughed at $29.6 million in Q1 2022.
  • A 5-year average of $36.1 million and a median of $33.8 million in 2021 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities rose 21.73% in 2021, then declined 8.69% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $32.0 million in 2021, then fell by 0.12% to $31.9 million in 2022, then grew by 15.65% to $36.9 million in 2023, then grew by 11.9% to $41.3 million in 2024, then climbed by 21.67% to $50.3 million in 2025.
  • Business Quant data shows SVRA's Total Non-Current Liabilities at $50.3 million in Q4 2025, $46.5 million in Q3 2025, and $43.3 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Savara 1.39 Bn 1.39 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 50.30 Mn
Sep 30, 2025 46.54 Mn
Jun 30, 2025 43.28 Mn
Mar 31, 2025 41.42 Mn
Dec 31, 2024 41.34 Mn
Sep 30, 2024 39.34 Mn
Jun 30, 2024 37.77 Mn
Mar 31, 2024 36.23 Mn
Dec 31, 2023 36.95 Mn
Sep 30, 2023 35.24 Mn
Jun 30, 2023 32.10 Mn
Mar 31, 2023 31.07 Mn
Dec 31, 2022 31.95 Mn
Sep 30, 2022 31.17 Mn
Jun 30, 2022 29.65 Mn
Mar 31, 2022 29.63 Mn
Dec 31, 2021 31.98 Mn
Sep 30, 2021 32.01 Mn
Jun 30, 2021 31.02 Mn
Mar 31, 2021 32.45 Mn